The Role of Inflammatory Cascade and Reactive Astrogliosis in Glial Scar Formation Post-spinal Cord Injury Authors: Manini Bhatt, Muskan Sharma, Bodhisatwa Das Published: 2024 ABSTRACT Reactive astrogliosis and inflammation are pathologic hallmarks of spinal cord injury. After injury, dysfunction of glial cells (astrocytes) results in glial scar formation, which limits neuronal regeneration. The blood–spinal cord barrier maintains the structural and functional integrity of the spinal cord and does not allow blood vessel components to leak into the spinal cord microenvironment. After the injury, disruption in the spinal cord barrier causes an imbalance of the immunological microenvironment. This triggers the process of neuroinflammation, facilitated by the actions of microglia, neutrophils, glial cells, and cytokines production. Recent work has revealed two phenotypes of astrocytes, A1 and A2, where A2 has a protective type, and A1 releases neurotoxins, further promoting glial scar formation. Here, we first describe the current understanding of the spinal cord microenvironment, both pre-, and post-injury, and the role of different glial cells in the context of spinal cord injury, which forms the essential update on the cellular and molecular events following injury. We aim to explore in-depth signaling pathways and molecular mediators that trigger astrocyte activation and glial scar formation. This review will discuss the activated signaling pathways in astrocytes and other glial cells and their collaborative role in the development of gliosis through inflammatory responses.Graphical Abstract Introduction The spinal cord is an integral part of the central nervous system (CNS) and peripheral nervous system (PNS) and connects the brain to the entire body through a vast network of neural connections. Damage to this intricate neural network, including the spinal cord, can result in severe neurological conditions. Spinal cord injury (SCI) disrupts neuronal and vascular networks' structural and functional integrity, impairing their functions. The cervical spine region, followed by the thoracic and thoracolumbar spine regions, is most susceptible to SCI (Brockie et al. 2024). The destruction of neural networks can lead to permanent sensory and motor dysfunction, paralysis, and disturbance of bladder and rectal function (Kobayakawa et al. 2019). Every year, around 3,75,000 (approx.) people are affected by SCI, and over 2–3 million are injured globally. Developed countries like Canada and the USA have more prevalent cases of SCI. Possible causes of SCI include accidents (falls), sports injuries, gunshot wounds, or surgical complications (Quadri et al. 2020). The cellular component of the spinal cord includes neurons and glial cells (astrocytes, microglia, oligodendrocytes (OLs)). The imbalance of the spinal cord microenvironment is primarily caused by the actions of glial cells and lymphocytes, the production of numerous cytokines, and the breakdown of the spinal extracellular matrix (ECM). In general, two types of SCI are primary and secondary injury. Primary and secondary injury events activate resident astrocytes, microglia, and other glial cells while facilitating peripheral immune cell infiltration. The interaction between these cells contributes to the formation of glial scar, inflammation, ionic imbalance, and free radical generation, all inhibiting axonal regeneration and myelination (Pang et al. 2021). Surrounding the spine is the blood–spinal cord barrier, which helps maintain the spinal cord injury. Damage to this barrier primarily triggers the inflammatory responses following the injury. Together these responses form a scar around the injury, which helps prevent further damage to the injured tissue (Wang et al. 2022). Another approach to prevent this damage is stem cell therapy. Moreover, MSCs play a prominent role in tissue repair and regeneration, as they secrete bioactive molecules that help reduce inflammation and promote neurons and tissue repair (Fathi et al. 2020). This regenerative property of MSCs can be maintained by niche, and MSCs rely on the niche signal to maintain homeostasis and tissue repair. Boosting the niche environment, such as ECM composition, or adding some growth factor could improve the repair of the spinal cord (Farahzadi et al. 2023). Stem cell therapy, along with biomaterials such as scaffolds, contributes towards the repression of inflammation and improving spinal cord restoration. MSCs can initiate cytokine production, which contributes to spine injury recovery. In this review, we examine the role of these cellular components in spinal cord injury and their crosstalk in inflammatory cascades, which eventually lead to the formation of glial scars. SCI Microenvironment The ECM and other biological fluids envelop the spinal cord. The ECM in the CNS constitutes a three-dimensional structural framework that supports cells such as astrocytes, glial cells, and OLs. In a healthy CNS, ECM includes perineuronal nets (PNN), Interstitial space (IS), Chondroitin sulfate proteoglycans (CSP), fibronectin, Laminin, and basement membrane (Lau et al. 2013). These components play a crucial role in signal transmission, and these signaling functions can be used for SCI treatments. The primary function of ECM is to maintain stability and synapses, regulate cell migration, and provide axon guidance. The spaces between the cells are diffused more in the ECM than the basement membrane, along with the large amounts of glycoproteins and proteoglycans (CSP linked to hyaluronan) and less collagen and fibronectin. Moreover, fibronectin, laminin, and collagen help heal, regenerate, and repair wounds. Also, fibronectin helps in cell migration (Haggerty et al. 2017; Wiese and Faissner 2015). Blood–spinal cord barrier (BSCB) is the semipermeable barrier present between the CNS and the circulatory system. It comprises non-fenestrated endothelial cells (lack cell membrane fenestrations), basement membrane, capillary pericytes, and terminal processes of astrocytes. BSCB primarily acts as a protective interface between the spinal cord and the surrounding blood vessels. The permeability of BSCB is maintained by a complex protein network of tight junctions consisting of occlusive zone 1, occlusal protein, and blocking protein 5 (Jin et al. 2021). Although BSCB appears to be like a Blood–brain barrier (BBB), there are still many differences between them, which are elaborated in Table 1.Table 1Distinctive characteristics of BSCB and BBBDifferenceBSCBBBBGlycogen depositsPresent in the spinal cordAbsent in brainPermeabilityMore permeableLess permeableExpression of tight junctionsLessMoreExpression of adherence junctionLessMoreTransport proteinDecrease expression of antiporter P-glycoproteinExpression of antiporter P-glycoprotein high Table 1Distinctive characteristics of BSCB and BBBDifferenceBSCBBBBGlycogen depositsPresent in the spinal cordAbsent in brainPermeabilityMore permeableLess permeableExpression of tight junctionsLessMoreExpression of adherence junctionLessMoreTransport proteinDecrease expression of antiporter P-glycoproteinExpression of antiporter P-glycoprotein high Distinctive characteristics of BSCB and BBB The integrity of BSCB is linked to various CNS and PNS disorders, including SCI. Breakdown of BSCB and its related vascular tissue is the first consequence of SCI. As soon as the injury occurs, the permeability of BSCB is compromised, and the movement of molecules of blood vessels (including various cellular components) leaks into the spinal cord parenchyma. These trigger a pathophysiological cascade of glial scar formation, facilitating further damage to the barrier (Bartanusz et al. 2011). Cellular Components of SCI Glial cells, the supporting cells of neurons, are present in CNS at a ratio of ten times more than neurons. Glial cells are divided into two types: CNS glial cells and non-CNS glial cells. CNS glial cells include microglia, endogenous neural stem cells, astrocytes (Fan et al. 2016), and OLs (Kuhn et al. 2019). In normal conditions, these cells help maintain homeostasis (Oudega 2012). Glial cells undergo proliferation and migration, like astrocytes, endogenous neuronal stem cells (ENSC), microglia, and ECM (CSP). These cells and macrophages are recruited at the lesion site and reinforced into the glial scar (Barnabé-Heider et al. 2010). Selin et al. transplanted olfactory ensheathing cells (olfactory bulb and olfactory mucosa) at the site of SCI in an animal model. It was observed that olfactory mucosa secrete laminin, vascular endothelial growth factor (VEGF), neural cell adhesion molecule (NCAM), and Fibronectin, which was successful for ECM formation, improved angiogenesis and regulation of the inflammatory process. On the other hand, the olfactory bulb releases neurotrophins, neuregulin, and Brain-derived neurotrophic factor (BDNF), which helps in neuron proliferation and development along with axonal growth. Some clinical trials are ongoing (Ursavas et al. 2021). However, non-neuronal cell types (brain parenchyma) also come under glia. These cell types have distinct embryonic origins, programming, and mature expression patterns, which highlight how diverse they are from one another (Masgrau et al. 2017). Interestingly, these distinctive developmental cell sources show differences in adults. In recent studies, the RNA-sequencing method was used, and it was observed that various glial cell types exhibit significant variations in the protein expression profiles (Zhang et al. 2014a, b). Different glial cells have different characteristics, and their response to injury is also different, as shown in Table 2.Table 2Types of glial cells and their cellular characteristicsGlial cell typeFunctions in healthy CNSMarkersSignaling pathwayResponse in post-SCIReferencesAstrocytesMaintain homeostasis,Synthesis and maintenance of ECMNeuronal development, migration, and differentiation functionFormation of synapsesCytoplasmic markers:GFAP,Aldolase C,ALDH1L1, C3Nuclear marker:S100B,SoX9, MFGEB (type-2 parenchymal astrocytes)Activation of the Nuclear factor kappa B (NF-kB) pathwayGDNF signaling pathwaysSTAT3 signaling pathwaysRemoval of glutamateProliferation and secretion of neuroprotective growth factorsFormation of glial scarSofroniew and Vinters (2010)Escartin et al. (2021)Liddelow and Barres (2017)OligodendrocytesParticipate in axonal regulationRapid conduction (speed of signal) of the nerveSupports the function and survival of axonsOPCs:Differentiate into OLs,Immunomodulatory capacityCytoplasmic markers:Plp 1, Mog, OpallinNuclear marker:Olg1, Olg2, Sox10, St18Wnt signaling cascadeActivation of ERK1/2 pathwaysProduction of glycoproteins with Nogo- -receptor affinity that will suppress myelin productionMassive death due to high glutamate concentrationsBradl and Lassmann (2010)Herculano-Houzel and Santos (2018)Soomro et al. (2018)MicrogliaPromote neuronal survival, axon growth, and myelination in OLsControl synaptic density, connectivity, and plasticityPhagocytosisCytoplasmic markers:CX3cr1, Itgam, Iba-1/Aif1, P2ry12Nuclear marker:NIrp3,Irf8,spi1,Iba-1Activation of JAK/STAT- PathwayMAPK pathway affects phenotype transitionThey are, first, phagocytosing debris and producing neuroprotective factorsOver time, they become neurotoxic and growth-inhibitory due to constant activationXu et al. (2021)Tello et al. (2014)Herculano-Houzel and Santos (2018)Li et al. (2021)NeuronsThe functional part of CNSStimulate electrical and chemical signalsDelivers neuronal signalsCytoplasmic markers:Snap25,Sst,PvallbNuclear marker:NeuN,SnurfP2X4R and CXCR1 signalingLoss of neuronsEncourage ENSC developmentAlbert et al. (2021)Herculano-Houzel and Santos (2018) Table 2Types of glial cells and their cellular characteristicsGlial cell typeFunctions in healthy CNSMarkersSignaling pathwayResponse in post-SCIReferencesAstrocytesMaintain homeostasis,Synthesis and maintenance of ECMNeuronal development, migration, and differentiation functionFormation of synapsesCytoplasmic markers:GFAP,Aldolase C,ALDH1L1, C3Nuclear marker:S100B,SoX9, MFGEB (type-2 parenchymal astrocytes)Activation of the Nuclear factor kappa B (NF-kB) pathwayGDNF signaling pathwaysSTAT3 signaling pathwaysRemoval of glutamateProliferation and secretion of neuroprotective growth factorsFormation of glial scarSofroniew and Vinters (2010)Escartin et al. (2021)Liddelow and Barres (2017)OligodendrocytesParticipate in axonal regulationRapid conduction (speed of signal) of the nerveSupports the function and survival of axonsOPCs:Differentiate into OLs,Immunomodulatory capacityCytoplasmic markers:Plp 1, Mog, OpallinNuclear marker:Olg1, Olg2, Sox10, St18Wnt signaling cascadeActivation of ERK1/2 pathwaysProduction of glycoproteins with Nogo- -receptor affinity that will suppress myelin productionMassive death due to high glutamate concentrationsBradl and Lassmann (2010)Herculano-Houzel and Santos (2018)Soomro et al. (2018)MicrogliaPromote neuronal survival, axon growth, and myelination in OLsControl synaptic density, connectivity, and plasticityPhagocytosisCytoplasmic markers:CX3cr1, Itgam, Iba-1/Aif1, P2ry12Nuclear marker:NIrp3,Irf8,spi1,Iba-1Activation of JAK/STAT- PathwayMAPK pathway affects phenotype transitionThey are, first, phagocytosing debris and producing neuroprotective factorsOver time, they become neurotoxic and growth-inhibitory due to constant activationXu et al. (2021)Tello et al. (2014)Herculano-Houzel and Santos (2018)Li et al. (2021)NeuronsThe functional part of CNSStimulate electrical and chemical signalsDelivers neuronal signalsCytoplasmic markers:Snap25,Sst,PvallbNuclear marker:NeuN,SnurfP2X4R and CXCR1 signalingLoss of neuronsEncourage ENSC developmentAlbert et al. (2021)Herculano-Houzel and Santos (2018) Types of glial cells and their cellular characteristics Maintain homeostasis, Synthesis and maintenance of ECM Neuronal development, migration, and differentiation function Formation of synapses Cytoplasmic markers: GFAP, Aldolase C, ALDH1L1, C3 Nuclear marker: S100B, SoX9, MFGEB (type-2 parenchymal astrocytes) Activation of the Nuclear factor kappa B (NF-kB) pathway GDNF signaling pathways STAT3 signaling pathways Removal of glutamate Proliferation and secretion of neuroprotective growth factors Formation of glial scar Sofroniew and Vinters (2010) Escartin et al. (2021) Liddelow and Barres (2017) Participate in axonal regulation Rapid conduction (speed of signal) of the nerve Supports the function and survival of axons OPCs: Differentiate into OLs, Immunomodulatory capacity Cytoplasmic markers: Plp 1, Mog, Opallin Nuclear marker: Olg1, Olg2, Sox10, St18 Wnt signaling cascade Activation of ERK1/2 pathways Production of glycoproteins with Nogo- -receptor affinity that will suppress myelin production Massive death due to high glutamate concentrations Bradl and Lassmann (2010) Herculano-Houzel and Santos (2018) Soomro et al. (2018) Promote neuronal survival, axon growth, and myelination in OLs Control synaptic density, connectivity, and plasticity Phagocytosis Cytoplasmic markers: CX3cr1, Itgam, Iba-1/Aif1, P2ry12 Nuclear marker: NIrp3, Irf8, spi1, Iba-1 Activation of JAK/STAT- Pathway MAPK pathway affects phenotype transition They are, first, phagocytosing debris and producing neuroprotective factors Over time, they become neurotoxic and growth-inhibitory due to constant activation Xu et al. (2021) Tello et al. (2014) Herculano-Houzel and Santos (2018) Li et al. (2021) The functional part of CNS Stimulate electrical and chemical signals Delivers neuronal signals Cytoplasmic markers: Snap25, Sst, Pvallb Nuclear marker: NeuN, Snurf Loss of neurons Encourage ENSC development Albert et al. (2021) Herculano-Houzel and Santos (2018) Astrocytes Astrocytes are the glial cells of the CNS, which are derived from neural stem cells. These are also known as “star cells” or “astroglia” and are made up of 20–40% of the CNS cells. The functions and essential characteristics are described in Table 2 (Liddelow and Barres 2017). Astrocyte cell division after traumatic SCI is initially triggered by immediate disruption of the local environment such as ECM and BSCB breakdown, pro-inflammatory cytokines release, and infiltration of immune cells. This all leads to astrocyte activation to become reactive astrocytes. JAK/STAT3 pathways are activated after injury and promote the proliferation, and further formation of glial scar along with the upregulation of Glial fibrillary acidic protein (GFAP), Interleukin (IL)-1 β, and vimentin. Eventually, they developed into glial scarring astrocytes that release axonal growth inhibitors and hinder axonal repair (Hu et al. 2021). In normal conditions, astrocytes are nondividing cells. The reactivation of these cells leads to cell division which occurs after injury to the microenvironment of the spine or they are external signals driven. Moreover, astrocyte division after SCI is a critical component of the injury response and also plays a significant role in limiting axonal repair in SCI. Types of Astrocytes and Their Signaling Pathways According to the neuroinflammation model, there are two types of astrocytes: A1 astrocytes (A1a) and A2 astrocytes (A2a). A1a releases a soluble toxin that destroys CNS neurons and mature OLs, whereas other CNS cell types are unaffected. The A1a function is significantly diminished; for instance, fewer A1a induce synapse formations, and these synapses are insufficient in their functions. Moreover, it has been demonstrated that A1a upregulates several complement cascade genes harmful to synapses. As a result, A1a was viewed as a potentially dangerous type (Liddelow and Barres 2017). According to Liddelow et al., complement component 3 (C3) (A1a marker) increases immunofluorescence as early as three days after SCI. Activated microglia induce the stimulation of A1a (Liddelow et al. 2017). Chemical mediators like interleukin (IL)-α, tumor necrosis factor (TNF)-α, and Complement component subunit 1q (C-1q) are produced by microglia and result in astrocyte polarization (Sonn et al. 2020) and activation of the NF-kB pathway which further enhance the production of C3 marker and Complement factor B (CFB). One or two genes cannot induce astrocyte polarization. Hence, all three genes work together to induce astrocyte polarization. NF-kB pathway activations cause pathogenic alternations in the CNS, while its suppression slows the spread of disease according to mounting evidence (Brambilla et al. 2009). Another study showed that through the Wnt/β-catenin pathway, IL-4-induced M2 macrophages promote chemotaxis and astrocyte activity of reactive astrocytes in SCI. When the Wnt/β-catenin pathway was inhibited, the elongated astrocytes percentage decreased and was more randomly oriented (Sonn et al. 2020). A2a has been demonstrated to upregulate several neurotrophic factors, anti-inflammatory, cytokines, and transforming growth factor-β (TGF-β), and these factors promote axon formation and neuroprotection (Diniz et al. 2014). Thus, in contrast to A1, A2a may be a protective type. However, there is a new marker for A2 astrocytes, i.e., S100A10 (belongs to the S100 protein family). The primary influential role of S100A10 in A2a is cell proliferation, inhibition of cell death, and membrane repair (Fujita et al. 2018). Activation of the signal transducer and activator of the transcription-3 (STAT3) pathway perform many functions that oppose the NF-kB pathway. Downregulation of GFAP will knock out the STAT3 from astrocytes, which fail hypertrophy, scar formation of astrocytes after SCI, and eventually impaired motor function (Herrmann et al. 2008). Okada et al. used a mouse model of SCI and investigated the translocation of STAT3 in reactive astrocytes (Okada et al. 2006). However, conditional ablation of STAT3 in astrocytes inhibited normal scar formation and increased inflammation, lesion growth, and motor impairment in mice with L1/L2 moderate crush damage (Herrmann et al. 2008; Wanner et al. 2013). Hashioka et al. discovered that in the post-acute phase of SCI, miR-21 acts as a molecular switch that regulates the reactive astrogliosis by TGF-β signaling (Liu et al. 2018). Recently, Liu et al. showed that miR-21 is a molecular switch to control astrocyte polarization. A1a was transformed into A2 astrocytes when miR-21 was downregulated. On the other hand, upregulation of miR-21 leads to the transformation of A2a into A1a. Moreover, the STAT3 pathway mediates these functions. A2a regulated by miR-21 enhances neurite growth and synapse formation by directing Gpc6 and Glial cell-derived neurotrophic factor (GDNF) signaling pathways (Su et al. 2019). Researchers have also suggested that loss of astrocytes in SCI may cause autoimmune disease, neurological tumors, and other CNS disorders (Voskuhl et al. 2009; Li et al. 2020a, b). So, the polarization from A1a to A2a is essential to prevent scar formation and to remove neuronal regeneration in SCI. Astrocyte Heterogeneity Until now, we have been discussing predominantly about A1 and A2 phenotypes of astrocytes, one being neurotoxic and the other neuroprotective. Recent research has shown that astrocytes are a heterogeneous set of cells, and the A1 vs. A2 distinction is insufficient to account for the diversity of reactive astrocytes. Researchers used RNA sequencing to characterize this variation among these cells and discovered that reactive astrocytes exhibit distinct behaviors based on the disease type and the location of their presence in the brain. This primarily entails astrocytes losing their original function and acquiring new skills. All of this demonstrates that it is not warranted to classify astrocytes as either neuroprotective or neurotoxic. Reactive astrocytes cannot be understood with these descriptors since they are too ambiguous (Escartin et al. 2021). The most recently investigated field for characterizing the alterations that take place in normal astrocytes is the study of homeostatic genes. Cuautle et al., in their study, described reactive astrogliosis because of exposure to LPS. This exposure led to methylation of DNA at the CpG island promoter which downregulates the Homeostatic gene inducing neural inflammation. Decitabine drug was then used to stop the DNA methylation and eventually homeostasis was restored in astrocytes. This prevented further damage to the neurons (Cuautle et al. 2024). The classification of astrocytes as homeostatic and Disease-associated astrocytes was also studied in Alzheimer’s disease. However, this classification may also vary from disease to disease (Habib et al. 2020). Therefore, a deeper understanding of reactive astrocytes is needed, where all the variables, such as the transcriptomics, the shape, and the behavior of these cells, are examined in a disease-specific manner. Oligodendrocytes Initially, OLs were named “oligodendrocyte type-2 astrocytes progenitor cells” because, under specific conditions, they develop either into type-2 astrocytes or OLs and later were called “Oligodendrocytes precursor cells” (OPC) due to its demyelination nature. Acute loss of OLs was seen within 15 min after SCI in rats (Ma et al. 2024; Casha et al. 2001). After rat spinal contusion, prolonged OL apoptosis has been seen for at least three weeks; dying cells were particularly noticeable in degenerating axon tracts rostral and caudal to the injury site (Guest et al. 2005). Primary SCI (within 2 h) causes traumatic cell disability, spinal shock, dysfunction, necrosis, and apoptosis, which further promotes the demyelination of axons. Adenosine triphosphate (ATP) level is elevated in primary SCI, and ATP and glutamate trigger the intracellular pathway, leading to cell apoptosis (Domercq et al. 2010). Two well-known agents that influence the growth of the oligodendrocyte lineage include Fibroblast growth factor-2 (FGF-2) and Platelet-derived growth factor-A (PDGF-A) (Chen et al. 2007). However, Wnt exhibits a dual role; it inhibits the development of OPC from neural progenitors at the early stage and their differentiation into immature OLs in the late stage. Hence, the Wnt signaling cascade plays a crucial role in the proliferation and differentiation of OPC (Soomro et al. 2018). Glutamate receptors like N- methyl-D-aspartate (NMDA) receptor release help in OPC maturation and myelination in dorsal root ganglions (Xiao et al. 2013), and during myelination, AMPAR activation helps in proliferation and differentiation (Mangin and Gallo 2011). Hence, we can say that the significant role of OLs is the demyelination of axons at the time of injury. Microglia Microglia are derived from the circulating monocytes from the bone marrow and then enter the CNS, making up around 5–10%. For microglial survival throughout life, one of the CSF receptor's two ligands, CSF-1 or IL-34, must be activated (Zha et al. 2025). Indispensable molecules like interferon intrinsic factor (IRF8) and TGF-β are responsible for microglial development (Utz et al. 2020). Communication between a cluster of differentiation (CD) 200 and CD200R is required to maintain inactivated microglia. Subsequent tissue damage and persistent inflammation lead to secondary damage, which produces pro-inflammatory molecules and free radicals (Fan et al. 2016). In secondary damage, pro-inflammatory cytokines, microglia activation, chemokines, and leukocyte infiltration are key events (Yao et al. 2018). Interestingly, the ST2 marker, the particular IL-33 receptor that facilitates the microglial engulfment of synapses in the spinal cord and thalamus, is only expressed by microglia in these two regions (Vainchtein et al. 2018). Types of Microglia As there are many subgroups of microglia, activated microglia were first thought to be homogenous cells. After activation, microglia are divided into two cell types: M1 type (classical) and M2 type (selective), which are further subdivided, as shown in Fig. 1. Pro-inflammatory factors such as γ-interferon and Lipopolysaccharide (LPS) help in the transformation from resting microglia to M1 cells. The mechanism of M1 microglia is explained in Fig. 2 (Orihuela et al. 2016; Kigerl et al. 2018). Hence, M1-type microglia are frequently overactivated, exacerbating the subsequent inflammatory reaction storm and causing more neuronal cell death and tissue damage.Fig. 1The polarization of microglia and macrophages from monocytes involves complex interactions among cytokines, chemokines, and transcription factors. The macrophages/ microglia surface receptors bind with signaling molecules in the microenvironment, activating nearby signaling molecules and transcription factors, which govern this polarization pathway. The artwork used in this figure was adapted from Servier Medical Art (https://smart.servier.com//Powerpoint-image-bank). Servier Medical Art by Servier is licensed under a Creative Commons Attribution 3.0 Unported LicenseFig. 2The timeline after SCI is its molecular profile at four sequential stages. Following primary injury, the BBB gets disrupted at the first stage (within hours). Over the subsequent days, extensive upregulation of cytokines and infiltration of immune cells. This is followed by the activation of astrocytes, which form a glial scar to shield the surrounding tissue. Eventually, limited structural tissue regeneration occurs from several weeks to months post-SCI. These time points are reviewed in the study (Rust and Kaiser 2017)Fig. 3The inflammatory responses post-SCI involve intracellular signaling cues and cytokines. JAK Janus kinase, TRADD TNFR1 associated via death domain, IKK IkappaB kinase, P Protein kinase, TRAF TNF receptor-associated factor, MEK Mitogen-activated protein kinase, ERK Extracellular signal-regulated kinase, IRK IL-1 receptor-associated kinase, KEAP Kelch-like ECH-associated protein, NRF Nuclear factor erythroid 2-related factor. The artwork used in this figure was adapted from Servier Medical Art (https://smart.servier.com//Powerpoint-image-bank). Servier Medical Art by Servier is licensed under a Creative Commons Attribution 3.0 Unported License The polarization of microglia and macrophages from monocytes involves complex interactions among cytokines, chemokines, and transcription factors. The macrophages/ microglia surface receptors bind with signaling molecules in the microenvironment, activating nearby signaling molecules and transcription factors, which govern this polarization pathway. The artwork used in this figure was adapted from Servier Medical Art (https://smart.servier.com//Powerpoint-image-bank). Servier Medical Art by Servier is licensed under a Creative Commons Attribution 3.0 Unported License The timeline after SCI is its molecular profile at four sequential stages. Following primary injury, the BBB gets disrupted at the first stage (within hours). Over the subsequent days, extensive upregulation of cytokines and infiltration of immune cells. This is followed by the activation of astrocytes, which form a glial scar to shield the surrounding tissue. Eventually, limited structural tissue regeneration occurs from several weeks to months post-SCI. These time points are reviewed in the study (Rust and Kaiser 2017) The inflammatory responses post-SCI involve intracellular signaling cues and cytokines. JAK Janus kinase, TRADD TNFR1 associated via death domain, IKK IkappaB kinase, P Protein kinase, TRAF TNF receptor-associated factor, MEK Mitogen-activated protein kinase, ERK Extracellular signal-regulated kinase, IRK IL-1 receptor-associated kinase, KEAP Kelch-like ECH-associated protein, NRF Nuclear factor erythroid 2-related factor. The artwork used in this figure was adapted from Servier Medical Art (https://smart.servier.com//Powerpoint-image-bank). Servier Medical Art by Servier is licensed under a Creative Commons Attribution 3.0 Unported License In contrast to M1 microglia, M2 microglia plays a significant role in neural differentiation, tissue repair, and inflammatory responses (Cherry et al. 2014). M2 microglia are activated by IL-10, IL-4, and TNF-β. Anti-inflammatory microglia are another name for M2 microglia. M2 microglia are further divided into M2a, M2b, and M2c subtypes. (David and Kroner 2011). M2 type is activated within a few hours of SCI and is anti-inflammatory. Continuous spinal cord stimulation and microglia divide lead to the phenotype change from M2 to M1 cells within a few hours to several days. M1 cells secrete inflammatory factors that help excrete neurotoxic effects. M1 type becomes a significant cell type of microglia after entering subacute and chronic phases, continuously stopping SCI and promoting tissue repair (Hu et al. 2015). Hence, activations of M2 microglia and deactivation of M1 microglia will be critical factors in treating SCI. In recent years, scientists have found different new states of microglia in response to diseases like Alzheimer’s disease. These disease-associated microglia (DAM) were later examined for Spinal cord injury by many researchers. One of the studies conducted by Hakim et al. described the role of DAM microglia in spinal cord injury by performing single-cell RNA sequencing on both healthy and injured spinal cord tissues. This enabled them to track alterations in baseline microglia from onset to chronic stages of injury. They discovered that baseline microglia undergo permanent alteration following SCI and convert into a cell stage similar to DAM. Later using mice models, it was confirmed that these injury-associated DAMs aid in enhancing hind limb mobility after SCI. (Hakim et al. 2021). Neurons It is electrically excitable cells that use synapses to communicate with other cells. The loss of neurons after SCI is the primary cause of limited recovery. The inhibitory elements around the microenvironment of SCI encourage ENSC development into more astrocytes, which affects ENSC differentiation. Increasing growth factors and decreasing inhibitors of imbalance microenvironment are to promote neuron differentiation by cell programming method (Grande et al. 2013; Heinrich et al. 2014). Lesser neuropathological changes, less neuron cell death, and reduced NADPH oxidase 2 (NOX2) and nucleotide-binding domain leucine-rich pyrin (NLRP3)-associated neuroinflammation were observed when mice were treated with PLX5622 (Henry et al. 2020). Neuropathic pain is often known as chronic pain caused by nerve injury and is frequently difficult to treat with medications available in the market (Inoue 2017). The progression and persistence of neuropathic pain are known to be intimately correlated with severe neuroinflammation, in which pro-inflammatory cytokines and chemokines play a significant role (Zhang et al. 2017). Therefore, early-state allodynia of nerve injury can be reduced by spinal blockage of P2X4R and CXCR1 signaling (Chen et al. 2018). Melatonin (Lee et al. 2014) and valproic acid (Lu et al. 2019) also promote endogenous stem cells. Also, the regenerative medicine strategy helps restore endogenous neural stem cell activation for SCI repair (Gilbert et al. 2022). Neuronal Inflammation Response to SCI Neuronal inflammation is an inflammatory response caused by chemical mediators like ROS, cytokines, and secondary messengers after SCI. However, the rate of neuroinflammation depends on duration, course of primary insult, and context, which is explained in (Fig. 2) (Fu et al. 2022). According to the severity of the injury, the rate of inflammation occurs. After SCI, almost 2 million new cells are produced at the injury site. The process of generating new neurons from neural stem cells is known as neurogenesis. The mechanical damage to neural tissue leads to cell death and the breakdown of BBB and BSCB after SCI. The infiltration of many inflammatory cells and macrophages/microglia is triggered by this primary event (DiSabato et al. 2016). This event tries to release inhibitory molecules like ROS and clears cell debris. The injury progresses to secondary damage over time, in which more neurons die due to inflammation, oxidative stress, and excitotoxicity. Ependymal cells are the primary source of endogenous neural stem cells in the adult spinal cord. These cells rarely divide at homeostasis, but it has been demonstrated that there is a massive increase in their proliferation within 24 h after injury. Many proliferating ependymal cells have a parallel division plane to the surface, implying that a newborn cell may remain in the ependymal layer and eventually migrate. In 3–7 days of SCI, these activities often trigger the proliferation, migration, and differentiation of Neural stem cells to mature neurons (Rodríguez-Barrera et al. 2021). Moreover, ependymal cells, as well as certain transcription factors, appear to be potential therapeutic targets. Neurogenic niche biology in disease situations is an area for further research in the Spine. Role of Microglia/Macrophages in Neural Inflammation In the spinal cord, macrophages are majorly responsible for inflammatory response and can be derived from resident microglial or peripheral circulating cells (Anwar et al. 2016). M1 macrophages are pro-inflammatory, and IRF5, NF-KB, and STAT1 signaling factors activate them. They show upregulation of reactive oxygen species (ROS) and IL-12 and downregulation of IL-10, which helps remove dead cells and cell debris and boosts inflammation. On the other hand, M2 macrophages are anti-inflammatory and are activated by STAT3, IRF4, STAT6, and Kruppel-like transcription factor-2 (KFL2). It plays a significant role in cell proliferation, maturation, migration, ECM synthesis, and tissue repair (Gensel and Zhang 2015). Under local conditions, microglia/macrophages exhibit phenotypic plasticity. The two primary phenotypic categories are M1 and M2, which help maintain homeostasis (Durafourt et al. 2012). Macrophages or microglia have the same expression of the Colony-stimulating factor 1 receptor (Csf1r), CD115, MER proto-oncogene tyrosine-protein kinase (MTK), ionized calcium-binding adaptor molecule-1 (Iba-1), and CD11b. Therefore, it is difficult to differentiate between macrophages and microglia. Reactive oxygen species (ROS) are detected in high concentrations during acute response to trauma. These factors cause the M1 macrophages or microglia to occupy a dominating condition in SCI, which harms SCI repair (Kigerl et al. 2009). The change in phenotype from M1 to M2 macrophages, where M2 macrophages downregulate the expression of pro-inflammatory cytokines (Boutilier and Elsawa 2021) brings about the healing cascade. M2 macrophages are tissue repair-capable anti-inflammatory cells. At the early stage of SCI, the M2 macrophage count is low; after seven days, it further decreases. M2 Macrophages are an unfavorable microenvironment for post-SCI. So, it can be prevented by increasing TNF expression, which would prevent the conversion of M1 into M2 macrophages (Gensel and Zhang 2015). Whenever primary SCI occurs, the healing process occurs in three phases: first is the inflammation phase, which lasts for 1–2 days; the second phase is proliferation, which lasts for 2–10 days; and then the remodeling phase, which lasts for a month (Gurtner et al. 2008). In the remodeling phase, the M2c phenotype upregulates the expression of TGF- β, CD206, and CD163 and downregulates the expression of IGF1, VEGF, and arginase-1, which is associated with M2a or M2b phenotype (Lawrence and Natoli 2011). Persistence in injury leads to secondary SCI, which causes ROS formation, lipid peroxidation, and transcriptional control of macrophage activation. After SCI, ROS, and reactive nitrogen species are formed. M1 macrophage activation is through ROS and NF-kB cells (Brüne et al. 2013). Due to the general effects of available antioxidants, it is difficult to determine specific ROS effects (Gloire et al. 2006). 4-Hydroxynonenal and acrolein are the byproducts of lipid peroxidation. These byproducts increased after SCI, and they covalently bind to protein structures and interfere with typical protein functions (Xiong et al. 2007). Oxidatively altered lipoproteins and lipids trigger the activation of macrophage toll-like receptors (TLR). For example, TLR heterodimers and low-density oxidized lipoprotein bind to CD36 to activate the pro-inflammatory pathway (Seimon et al. 2010). Lipid-induced activation of TLRs in macrophages results in the generation of pro-inflammatory genes and an M1-like phenotype, which activates MAP kinase, NF-kB, and ROS-dependent signaling pathways (Adamson and Leitinger 2011). Moreover, an increase in low-density oxidized lipoprotein reduces the activity of the anti-inflammatory transcription factor, KLF2, and causes M2 macrophages to adopt a pro-inflammatory phenotype (Van Assche et al. 2011). Another transcriptional factor in macrophages, i.e., PPAR, and its activation produces M2 markers like Ym1, Arg1, CD206, and FIZZ1. Human monocytes differentiate into M1 macrophages due to PPARγ activation, which enhances M1 macrophage's anti-inflammatory function (Bouhlel et al. 2007) (Fig. 3). Macrophages and microglia have distinct functions and responses during pathology. Recent studies have identified that macrophages retained persistent phagocytic debris and were more vulnerable to necrotic cell death than microglia, which were better at removing phagocytosed debris. Another difference is that in SCI, the anti-inflammatory enzyme arginase-1 was upregulated in macrophages but not in microglia (Greenhalgh et al. 2016). Lower expression of CD45 for macrophages distinguished it from microglia. Jordao et al. and Goldmann et al. studies have shown that microglia and border-associated Macrophages have different transcriptomic signatures (Goldmann et al. 2016; Jordão et al. 2019). Compared to microglia, macrophages migrate more quickly and are more accountable for secondary axon injury. These infiltrative macrophages can interpret this phenomenon and persist for much longer in phagocytosing material (Greenhalgh and David 2014). Infiltrative macrophages modulate each other's functions differently and suppress the phagocytic function of microglia and pro-inflammatory action. It has been observed that neutrophils and macrophages are more occupied at the site of injury than microglia (Greenhalgh et al. 2018). It is still necessary to learn more about the different roles played by macrophages and microglia and their interactions. Cellular Crosstalk in Glial Scar Formation Primary damage in SCI involves damage to BSCB, surrounding vasculature, and neuronal tissue. Inflammatory response is the most studied component of secondary response that decides the fate of SCI. A prolonged inflammatory response can elevate damage to spinal cord parenchyma. The damaged cellular components (neurons and fibroblasts) release various DAMP and PRR signals, which trigger the release of cytokines and ROS from BSCB, astrocytes, and microglia. The neuronal cells and infiltered peripheral immune cells mediate the initiation of neural inflammation and the formation of glial scars. (Pang et al. 2021). Fibrotic Scar (Primary Scar) After initial tissue damage due to SCI, it produces cellular debris, which creates a toxic microenvironment at the injury site. Microglia and astrocytes act as phagocytotic agents for clearance of this debris; during this process, they release various cytokines and chemokines that facilitate the movement of immune cells at the lesion site. Neutrophils are the first type of immune cells that are predominant during the first 24 h after injury. Neutrophils mediate inflammation via phagocytosis and removal of cell debris at the injury site. They also help in the repair by secretion of leukocyte protease inhibitors (Pang et al. 2021). Neirinckx et al. reviewed the fact that neutrophils, along with macrophages, guide the inflammation process. Neutrophils are responsible for wound repair in SCI up to some extent. They have been observed to release angiogenic factors and induce vasculature in damaged spinal tissue remodeling (Neirinckx et al. 2014). Monocyte and microglia-derived macrophages are the following line of immune cells chemotactically introduced at the injury site by neutrophils. Macrophages are active at the lesion site for around seven days post-injury. M1 and M2 macrophages are based on expressing cell surface markers and secretory molecules (Sica and Mantovani 2012). M1 is responsible for demyelination and hindering axonal regeneration, while M2 primarily works to clear dead cellular debris and promote axonal regeneration. The ECM at the injury site comprises non-neuronal cells, including stromal fibroblast cells (later form fibrocytes), and together, the crosstalk of non-neuronal and immune cells in the injury ECM forms the fibrotic scar, which occupies the core of lesion is shown in Fig. 4.Fig. 4The spinal cord injury scar with both fibrous and astrocyte scar. A fibrotic scar is present at the lesion core, which makes the primary scar predominated by phagocytotic macrophages. It is later surrounded by a secondary scar formed by astrocytes via astrogliosis. This prevents inflammatory cells from causing further damage to healthy neural cells surrounding the injury site The spinal cord injury scar with both fibrous and astrocyte scar. A fibrotic scar is present at the lesion core, which makes the primary scar predominated by phagocytotic macrophages. It is later surrounded by a secondary scar formed by astrocytes via astrogliosis. This prevents inflammatory cells from causing further damage to healthy neural cells surrounding the injury site Astrogliosis (Secondary Scar) After seven days of injury, macrophages activate scar-forming astrocytes, facilitating astrogliosis. Reactive astrocytes have two phenotypes (A1 and A2) with different cell markers and gene expression. Astrocytes migrate and proliferate around fibrotic scars. The primary role of these cells is to separate inflammatory cells inside the core of the fibrotic scar and prevent them from damaging surrounding undamaged neuronal cells. These bordering astrocytes later react with OLs and produce OPC, which releases neuron-glial antigen 2(NG2), also known as CSP 4. This cellular crosstalk among SCI cellular components completes the formation of a glial scar (gliosis) (Anjum et al. 2020). Role of Astrocytes in Astrogliosis When SCI occurs within a few hours of injury, neural tissue gets damaged, which causes swelling. In response to nerve damage, ATP activates a wide range of purinergic receptors which cause astrocytes, OLs, microglial activation, and neuropathic pain (Qaiser et al. 2024; Tatsumi et al. 2015). Therefore, swelling and pain are the acute inflammation response. Inflammatory factors like IL-1β, IL-6, and TNF can also trigger astrocyte activation (Liddelow et al. 2017). A significant increase of GFAP, CSP, STAT3 pathway (Herrmann et al. 2008), and NF-kB pathway (Brambilla et al. 2009) within a few hours of SCI indicates astrocyte activation. Typically, reactive astrocytes in an uninjured spinal cord are morphologically similar, but cellular hypertrophy and overexpression of GFAP reactive astrocytes differ (Wanner et al. 2013). After 1–2 days, astrocytes rapidly multiply, and within 7–9 days, they form a glial scar. The multiplication rate of astrocytes is fastest during 3–7 days after injury and slows down after the 7th day. It nearly stops after the 14th day of the injury. Throughout this procedure, astrocytes elongate perpendicular to the lesion core, and they gradually lose their domains and grow a thick limiting border around the lesion core, i.e., glial scar (Wanner et al. 2013; Hara et al. 2017). This procedure transforms astrocytes into scar-forming astrocytes, and these reactive astrocytes in neural tissue are very different from those that generate scars (Khakh and Sofroniew 2015). Scar-producing astrocytes are no longer perpendicular to the lesion site after completing their phenotypic transformation; instead, they become increasingly parallel and overlap. The glial scar fully develops after several weeks of injury and completely matures (Ren et al. 2017). From this point onwards, SCI lesions settle, and a protracted chronic regeneration phase starts. Following SCI, damaged axons could encounter a range of myelin-associated inhibitors originating from both OLs and myelin debris. With time, the glial scar attracts reactive astrocytes that release inhibitory CSP gradients, which promote axon regeneration (Li et al. 2020a, b). Also, immature astrocytes bind with chondroitinase ABC and encourage axonal regeneration (Filous et al. 2010). Hence, glial scar formation is prevented by fibroblasts, while axon regeneration is encouraged by astrocytes. Figure 5 depicts the transformation of astrocytes into scar-forming astrocytes and OPC's migration, proliferation, and differentiation.Fig. 5Schematic events of astrocytes, OPC, and OLs post-SCI. Astrocytes, OPC, and OLs rapidly respond after SCI by activating, proliferating, and migrating towards the lesion site. The reactive astrocytes are nearest the lesion to form dense meshwork, along with ECM forming a glial scar. This glial scar limits the axonal plasticity and inflammation. OLs are highly sensitive to perturbations and can undergo cell death or demyelination following SCI. Astrocytes and OLs secrete various cytokines and cytotoxic factors to communicate with other glial cells. The artwork used in this figure was adapted from Servier Medical Art (https://smart.servier.com//Powerpoint-image-bank). Servier Medical Art by Servier is licensed under a Creative Commons Attribution 3.0 Unported License Schematic events of astrocytes, OPC, and OLs post-SCI. Astrocytes, OPC, and OLs rapidly respond after SCI by activating, proliferating, and migrating towards the lesion site. The reactive astrocytes are nearest the lesion to form dense meshwork, along with ECM forming a glial scar. This glial scar limits the axonal plasticity and inflammation. OLs are highly sensitive to perturbations and can undergo cell death or demyelination following SCI. Astrocytes and OLs secrete various cytokines and cytotoxic factors to communicate with other glial cells. The artwork used in this figure was adapted from Servier Medical Art (https://smart.servier.com//Powerpoint-image-bank). Servier Medical Art by Servier is licensed under a Creative Commons Attribution 3.0 Unported License Role of Microglia in SCI After SCI, inflammation occurs, which activates the resting microglia cells. Activated microglia release cytokines (IL-1α, IL-1β), ATP, nitric oxide, TNF-α (David and Kroner 2011), DAMPs (Kigerl et al. 2014), and growth factors (Sanati et al. 2025). Microglia activation leads to upregulation of CD11b, Trem2, CD45, and Iba-1 and downregulation of CX3CR1, P2ry12, and Tmem119 (Mildner et al. 2017; Bennett et al. 2016). DAMPs include purine and protein, which initiate inflammation and are recognized by Pattern recognition receptors (PRR) (Schaefer 2014). TLR receptors such as TLR2 are a class of PRR and play a significant role in activating the NF-KB pathway. Macrophage activation and axonal injury are triggered by C-type lectin receptors (CLR) (Gensel et al. 2015). Another potent DMAP that is increased after SCI and linked with microglial activation and neurotoxic macrophage polarization is the High-mobility group box one protein (HMGB1). When HMGB1 binds to PRR, it results in inflammatory expression of IL-1β and TNF post-SCI (Kigerl et al. 2018). The activated microglia look for the pathogen or foreign cells and release cytokines that are helpful for the killing of foreign cells, which is explained in Fig. 6 (David et al. 2015). In the early stages of SCI, active microglia secrete trophic factors for proliferation and survival as well as axon growth and regeneration at the lesion site. Therefore, activated microglia serve a protective role by preventing the lesion from spreading. After 2–3 days, microglia induce macrophages to infiltrate the injured site and cause inflammation. The maximum proliferation of microglia near the lesion is from day 4 to day 7. Until the 14th day, microglia count continued to enhance at the injury site (Bellver-Landete et al. 2019). Macrophages can persist for 42 days near an injured lesion. Hence, we can say that macrophages play a significant role in the inflammatory response in the spinal cord.Fig. 6Schematic events of microglia after SCI. In response to SCI, microglia activate, proliferate, migrate, produce cytokines, and massive neuroinflammation. Microglia disrupts the BSCB, which enables leukocyte infiltration, cytotoxicity, and axon demyelination. The artwork used in this figure was adapted from Servier Medical Art (https://smart.servier.com/ /Powerpoint-image-bank). Servier Medical Art by Servier is licensed under a Creative Commons Attribution 3.0 Unported License Schematic events of microglia after SCI. In response to SCI, microglia activate, proliferate, migrate, produce cytokines, and massive neuroinflammation. Microglia disrupts the BSCB, which enables leukocyte infiltration, cytotoxicity, and axon demyelination. The artwork used in this figure was adapted from Servier Medical Art (https://smart.servier.com/ /Powerpoint-image-bank). Servier Medical Art by Servier is licensed under a Creative Commons Attribution 3.0 Unported License Cell debris is phagocytosed and broken down into small molecules. Phagocytosis of cell debris is necessary for the healing after SCI. The phagocytosis marker, i.e., lysosome-associated glycoprotein CD68, is low on day 1 of the injury, but it gets upregulated on day 4. Upregulation of CD68 directly enhances phagocytosis activity. From day 14 to day 35, microglia gradually downregulated the expression of CD68 and upregulated the expression of P2ry12, which helped bring the body back to homeostasis. Microglia takes these broken-up pieces out on its surface (antigen-presenting) for the other cells to see, especially other immune cells such as lymphocytes. Lymphocytes recognize the debris and cause inflammation, (Xu et al. 2021). Hence, microglia are activated by inflammation, and it also contributes to inflammation. Furthermore, microglia play a critical role in forming an astrocyte scar because they secrete cytokines like Insulin-like growth factor (IGF)-1 that support the proliferation and activation of astrocytes (Bellver-Landete et al. 2019). Role of Oligodendrocytes in SCI Different growth factors and cytokines are upregulated within minutes after injury, which can cause excitotoxicity. CNTF, an IL-6 family pleiotropic cytokine, has been demonstrated to support endogenous OPC migration in an acute demyelination model and spinal cord-derived OPC survival and differentiation in culture (Zhang et al. 2024; Talbott et al. 2007). In the case of SCI, upregulation of CNTF level improves functional recovery and promotes remyelination (Cao et al. 2010). Neurotrophins-3 is another factor that helps in proliferation differentiation and remyelination, and mammals' levels are enhanced after SCI (H.-T. Zhang et al. 2008). Upregulation of IL-17A, Myelin transcription factor 1 (MtF-1) (Wrathall et al. 1998; Wrathall et al. 1998; Wrathall et al. 1998; Wrathall et al. 1998; Manesh et al. 2024), IL-1β, and Leukemia inhibitory factor (LIF) occur after SCI (Pineau and Lacroix 2007). Moreover, by activating ERK1/2 pathways, OPCs are differentiated into mature oligodendrocytes (Rodgers et al. 2015). In acute secondary injuries (within two days), loss of OLs, axonal swelling due to monocarboxylate transporters-1 (Lee et al., 2012), and axon demyelination are promoted due to apoptosis and necrosis. The early mechanisms for the loss of OLs are damage to vessels by proteolytic enzymes, infiltrating neutrophils, oxidative stress, apoptosis, and necrosis. This loss of OLs impacts axons, resulting in chronic or progressive demyelination that extends beyond the lesion site (Buss et al. 2004). Shuxin et al. recent research shows that overexpression of bone morphogenic protein 7 is a multifunctional cytokine that reduces the loss of OLs and has preventive action against SCI (Liu et al. 2021). OPC proliferation is accelerated and prolonged, particularly along the lesion margins. Oligodendrocyte transcription factors (OLTF)1 and OLTF2 both eliminate the formation of OPCs. Moreover, in the contused spinal cord, OLTF2 expression is upregulated (Zhang et al. 2014a, b). Following SCI, OLs are especially vulnerable to the toxicity of the initial lesion environment (Almad et al. 2011). Numerous growth factors such as TNF-α, IL-1β, and cytokines are released at the site of injury, and OPC present in the spinal cord responds to injury along with these growth factors and cytokines. OPC proliferates and migrates to denuded axons, where it converts into mature OLs due to axonal signal resulting in remyelination of axons (Plemel et al. 2014). Additionally, ATP could be produced and delivered to axons by myelinating OLs via connexons, a gap junction protein. As a result, the speed of action potential conduction is enhanced. Conclusions In this review, we briefly describe the role of glial cells in SCI. Glial cells are the most fascinating cells in the SCI microenvironment, with the innate capability of forming scar tissue at the injury site. The overall development of the injury scar and its fate depends on well-organized crosstalk between astrocytes and the spine microenvironment. Among glial cells, reactive astrocytes promote astrogliosis, which restricts inflammatory cells (neutrophils, microglia, and macrophages) inside the scar core (fibrotic scar) and prevents them from causing further damage to the surrounding spinal parenchyma. Astrogliosis constrains axon plasticity or poor axonal regrowth, which limits functional recovery (inflammation). Further, we described the role of OLs, Microglia, neurons, and macrophages in SCI. Neuroinflammation causes secondary damage in addition to moderate axon plasticity and remyelination. Future Perspectives The evolving understanding of cellular and molecular mechanisms of reactive astrocytosis and inflammation cascade after SCI opens up new opportunities for future research and therapeutic strategies. Recovery from spinal cord injury is a challenging process, and it cannot be achieved using a single strategy. It requires a more synergistic approach, with collaboration among all fields of neuroscience to develop a comprehensive treatment plan for SCI. As a result, altering glial cell responses to SCI offers a possible path for therapeutic development. Researchers can use the timeline of gliosis and the crosstalk of inflammatory cascades to develop target therapies that can enhance repair and regeneration in damaged neural tissue. The significance of inflammation-related immune response is understudied, possibly due to the difficulties of developing an adequate animal model. With the advent of contemporary biotechniques, novel models such as organoids may be used to examine the detailed mechanism of SCI. Tailoring of inflammatory molecules or pathways is likely to provide fresh hope for treating SCI, which needs to be systematically and comprehensively studied. Future studies should focus on selective modulation of astrocyte phenotypes or restoring the damaged BSCB integrity through targeted modulation in the molecular signaling pathways, which will help control the inhibition of glial scar formation.